GLP-1 + GHS (Semaglutide + Tesamorelin or CJC/Ipa)

No high-quality controlled data. The rationale is mechanistic, and observational reports from metabolic clinics are mixed. Resistance training and adequate protein are far better-evidenced for lean-mass preservation during GLP-1 weight loss.

Tesamorelin is the most logical pairing — it specifically targets visceral fat (the compartment most associated with metabolic disease) and has FDA approval with RCT data. CJC-1295/Ipamorelin is a broader GH stack that supports body composition and recovery more generally. The choice depends on whether the goal is targeted visceral fat reduction (tesamorelin) or general body composition optimization (CJC/Ipa).

Not directly. GHS peptides do not reduce GLP-1-related nausea, constipation, or gastric symptoms. The potential benefit is preserving lean mass that GLP-1 agonists tend to strip alongside fat. GH-mediated improvements in sleep and recovery may indirectly support the overall treatment experience, but this is anecdotal.

GLP-1 agonists (semaglutide, tirzepatide) are weekly injections — any day, any time. GHS peptides (CJC-1295/Ipamorelin) are daily, ideally before bed in a fasted state. There is no pharmacological interaction requiring specific spacing between the two. The weekly GLP-1 injection can be on any day of the week independent of the daily GHS schedule.

More extensive than either alone. Minimum: IGF-1 (every 3 months), fasting glucose and HbA1c (every 3 months), lipid panel (every 6 months), body composition via DEXA (baseline and every 6 months), liver enzymes (every 6 months). The combination of GLP-1-mediated insulin sensitization and GH-mediated insulin resistance creates competing metabolic effects that require closer glucose monitoring than either class alone.

GLP-1 agonists (semaglutide, tirzepatide) are the most validated pharmaceutical intervention for metabolic health, with robust trial data showing 10–20% weight loss, improved glycemic control, reduced cardiovascular events, and potential liver fat reduction. The addition of a GHS peptide is a practitioner-driven modification intended to address the major limitation of GLP-1 monotherapy: significant lean mass loss (25–40% of total weight lost). However, this combination lacks controlled trial data. The GLP-1 alone remains the evidence-based core of this stack. The GHS component is speculative and adds cost, injection burden, and monitoring requirements. Resistance training and high protein intake (1.2–1.6 g/kg/day) are far better-evidenced strategies for lean mass preservation during GLP-1 therapy.

Metabolic syndrome (elevated waist circumference, triglycerides, blood pressure, fasting glucose, and low HDL) is a primary target for GLP-1 agonists. Semaglutide has demonstrated improvements across nearly all metabolic syndrome criteria in clinical trials — reducing visceral fat, lowering triglycerides, improving fasting glucose, and modestly reducing blood pressure. Tesamorelin specifically targets visceral adipose tissue and has FDA-approved data showing visceral fat reduction in HIV-associated lipodystrophy. The GHS component may support metabolic health through GH-mediated lipolysis and body composition improvements. However, metabolic syndrome management should prioritize lifestyle modification (diet, exercise, sleep) as the foundation, with pharmacotherapy (including GLP-1 agonists) as a medical intervention under physician supervision.

Protein intake is the single most impactful dietary variable — aim for 1.2–1.6 g/kg of target body weight daily, distributed across 3–4 meals, to protect lean mass during GLP-1-mediated weight loss and support GH-stimulated protein synthesis. Minimize refined carbohydrates and added sugars to reduce glycemic variability and complement GLP-1's glucose-lowering effects. Time carbohydrate intake away from GHS injections (avoid carbohydrates 2 hours before bedtime GHS dosing) to prevent insulin-mediated blunting of GH release. A moderate caloric deficit (300–500 kcal/day) rather than aggressive restriction works synergistically with GLP-1's appetite suppression without triggering excessive metabolic adaptation. Adequate fiber intake (25–35 g/day) supports GLP-1's gastrointestinal effects and reduces common side effects like constipation.

The answer differs by component. GLP-1 agonists (semaglutide, tirzepatide) are weekly injections that can be taken in any fed state — their long half-life means meal timing around the injection is irrelevant. GHS peptides (CJC-1295/Ipamorelin, tesamorelin) are critically dependent on fasting state — they must be injected at least 2 hours after eating and 30 minutes before eating. Elevated blood glucose and insulin directly suppress GH release, reducing the GHS peptide effect by up to 50–70%. The practical protocol is straightforward: GLP-1 injection on any convenient day regardless of meals, and GHS injection before bed on an empty stomach. Do not conflate the fasting requirement of GHS peptides with intermittent fasting protocols — the requirement is simply a 2-hour food-free window around the GHS injection.